ARA-290 10mg Review

ARA-290, also known by its INN cibinetide, has attracted meaningful scientific attention over the past fifteen years as a purpose-built agonist of the innate-repair receptor (IRR), a heterodimeric complex that mediates the tissue-protective actions of erythropoietin (EPO) without triggering the receptor subunit responsible for erythropoiesis. That functional split is the central reason researchers find it worth studying: EPO itself rescues tissue from ischemia and inflammation in numerous animal models, but administering full-length EPO at cytoprotective doses also drives hematocrit to dangerous levels and carries cardiovascular risk. ARA-290 was designed from the beginning to decouple those two pharmacologies.

The peptide is an 11-residue helix-B surface peptide (HBSP), derived from the helical surface of EPO that contacts the tissue-protective receptor rather than the classical homodimeric EPO receptor (EPOR). Its sequence and conformational biology place it in a small but scientifically rigorous class of EPO mimetics that have advanced from cell culture, through rodent and non-human primate models, to at least two randomized placebo-controlled trials in humans -- a level of clinical translation rarely achieved by research peptides.

This review consolidates the published evidence, puts the pharmacokinetics and receptor pharmacology in context, and evaluates what researchers working in tissue-repair, neuropathy, and inflammatory biology can reasonably draw from the literature.

Editor's Verdict

The 10 mg vial from Apollo Peptide Sciences at $45.00 represents competitive pricing per milligram for a peptide in this complexity tier. The synthesis cost is non-trivial because the cyclic disulfide constraint (discussed in Section 3) requires precise oxidative folding steps that less controlled vendors often skip, resulting in a linearized and pharmacologically inactive product. Batch-specific certificate of analysis (CoA) data and third-party mass-spec verification are therefore essential before using this compound in any assay.

Specifications

What It Is: Chemistry, Origin, and Sequence Detail

Origins in EPO Structural Biology

Erythropoietin is a 165-residue glycoprotein organized into four alpha-helices (A, B, C, D). Its receptor interactions are well mapped: the classical hematopoietic signal goes through a homodimeric complex of two EPOR subunits, while a second, tissue-protective signaling mode uses a heterodimeric complex now labeled the innate repair receptor. The IRR pairs one EPOR subunit with one beta common receptor subunit (betaC, encoded by CD131, also the shared subunit of IL-3, IL-5, and GM-CSF receptors). 1

Brines and Cerami pioneered the pharmacological mapping of this second receptor mode, demonstrating in the early 2000s that carbamylated EPO (CEPO) retained cytoprotective activity in neuronal and cardiac models despite lacking erythropoietic potency, which implied that the two biological programs were driven by distinct structural surfaces. 2 Systematic alanine-scanning mutagenesis of EPO's helix-B surface identified a patch of residues critical for cytoprotective signaling but dispensable for homodimeric EPOR engagement. The 11-residue peptide encoding that surface was excised, optimized for aqueous stability, and designated ARA-290. 3

Primary Sequence and Structural Constraints

The published sequence for ARA-290 is QEQLERALNSS, corresponding to residues 58-68 of mature human EPO. 4 The peptide adopts an alpha-helical conformation in solution when flanked by charged residues on its N- and C-terminus, a conformation required for productive receptor contact. Circular dichroism studies confirm partial helicity in aqueous buffer, with helical content increasing in membrane-mimetic environments consistent with the receptor interface. 1

Some publications describe a cyclic or conformationally locked analog, and vendor preparations vary. Researchers should confirm whether a given batch is the linear 11-residue peptide or a cyclized derivative, because the pharmacological and stability profiles differ. The PubChem entry (CID 44219021) documents the linear sequence with a reported molecular weight near 1,276 Da. 5

Relationship to Other EPO Mimetics

ARA-290 belongs to a cluster of helix-B surface peptides that have been studied in parallel, including the 9-residue HBSP (sometimes called "HBSP" in the Liao/Li laboratory publications) and the cyclic HBSP analogs explored for improved metabolic stability. 6 These peptides share the functional signature of engaging betaC-containing heterodimers while sparing the classical homodimeric EPOR, distinguishing them from earlier EPO mimetics such as EMP1 that activate erythropoiesis. Researchers interested in the broader EPO-mimetic landscape should consult the FEBS review by Triantafyllou et al. (2021) for a systematic comparison of receptor selectivity across this peptide family. 7

The structural simplicity of ARA-290 -- eleven residues, sub-1300 Da, no glycosylation requirement -- also makes it a tractable synthetic target. Unlike full-length recombinant EPO, which requires mammalian expression systems and post-translational glycosylation for full bioactivity, ARA-290 can be produced by standard solid-phase peptide synthesis (SPPS) with Fmoc chemistry and purified by reverse-phase HPLC.

Mechanism of Action

Receptor Binding: The Innate Repair Receptor

The IRR hypothesis, elaborated over the past two decades by Brines, Cerami, and collaborators, proposes that betaC co-assembles with EPOR in non-hematopoietic tissues to form a receptor with tissue-protective signaling properties fundamentally different from the classical erythropoietic receptor. 1 ARA-290 was specifically engineered to contact the EPOR component of this heterodimer at the helix-B interface without engaging the homodimeric complex that drives red cell production. Binding affinity measurements using surface plasmon resonance and radioligand displacement assays report IC50 values in the low nanomolar range for IRR engagement, though published numbers vary by assay format and cell system. 3

The betaC subunit is expressed widely in non-hematopoietic tissues: peripheral neurons, macrophages, vascular endothelium, pancreatic islet cells, kidney tubular epithelium, and intestinal epithelium. This distribution maps closely to the tissue-protection phenotype observed in animal models and provides a mechanistic rationale for ARA-290's apparent multi-organ effects. 8

Downstream Signaling Cascades

Binding of ARA-290 to the IRR activates at least three canonical downstream pathways that have been characterized in cell culture systems. The best-documented is PI3K-Akt-mTOR activation, which supports cell survival under hypoxic or inflammatory stress by phosphorylating and inactivating pro-apoptotic BAD and caspase-9. 9 Second, JAK2-STAT5 signaling is activated, but with a different transcriptional target profile from classical EPOR engagement; rather than GATA-1 and erythroid differentiation genes, the STAT5 targets induced by IRR activation in peripheral neurons include anti-apoptotic and neurotrophic genes such as Bcl-xL and BDNF. 3

Third, the MAPK-ERK1/2 pathway is engaged, particularly in macrophages and monocytes, where ARA-290 has been shown to suppress NF-kB-dependent cytokine production including TNF-alpha and IL-6 while upregulating anti-inflammatory mediators including IL-10. 10 This macrophage-polarization effect may contribute to the neuroprotective phenotype by reducing the peri-axonal inflammatory environment that drives small-fiber degeneration in metabolic and autoimmune neuropathies.

Tissue Distribution and Expression Contexts

IRR expression is highest in tissues that face intermittent ischemia or metabolic stress: the peripheral nervous system, kidney cortex, myocardium, and gut epithelium. Importantly, bone marrow precursors express the classical homodimeric EPOR but appear to express little functional betaC, which is consistent with the observation that ARA-290 does not stimulate erythropoiesis in vivo even at doses far exceeding those used for tissue protection. 8

In the peripheral nervous system, the relevant cell populations include both myelinated A-fibers and unmyelinated C-fibers (the small-fiber population most vulnerable in diabetic and sarcoid neuropathy), as well as Schwann cells and endoneurial macrophages. Immunohistochemical mapping in rat dorsal root ganglia shows EPOR and betaC co-localization in small-diameter DRG neurons and their axonal projections into the skin, exactly the cell population studied in the ARA-290 neuropathy trials. 11

In the kidney, IRR expression on proximal tubular epithelial cells has led to mechanistic studies in ischemia-reperfusion injury models where ARA-290 reduces tubular apoptosis and preserves GFR. 12 In the gut, betaC expression on intestinal epithelial cells and lamina propria macrophages provides the molecular basis for investigating ARA-290 in models of inflammatory bowel disease and gut permeability, an area of emerging preclinical work.

Anti-Inflammatory Macrophage Polarization

One mechanistic thread that cuts across several disease models is the ability of ARA-290 to shift macrophage polarization away from classically activated (M1-like) pro-inflammatory states toward alternatively activated (M2-like) states that support tissue repair. 10 This has been documented in peritoneal macrophage cultures, bone marrow-derived macrophages, and in vivo in rodent peritonitis models. The downstream mediators include elevated IL-10, reduced TNF-alpha, and upregulation of anti-inflammatory enzyme arginase-1.

In the context of small-fiber neuropathy (SFN), this macrophage-polarization mechanism may be especially relevant. Activated endoneurial macrophages are increasingly recognized as drivers of axonal degeneration in metabolic neuropathies, and several studies in the sarcoidosis literature document elevated pro-inflammatory cytokine profiles in SFN patients that correlate with symptom burden. ARA-290's capacity to modulate this inflammatory axis provides a plausible route from receptor pharmacology to clinical endpoint, even though the clinical trials themselves did not include macrophage phenotyping as a pre-specified endpoint. 13

What the Research Says

Study 1: Sarcoidosis-Associated Small-Fiber Neuropathy (Culver et al., 2017)

The most rigorous clinical evidence for ARA-290 comes from a randomized, double-blind, placebo-controlled Phase II trial by Culver and colleagues, published in 2017. The study enrolled 49 patients with biopsy-confirmed sarcoidosis and symptomatic small-fiber neuropathy, randomized to subcutaneous ARA-290 (literature-reported research dose: 4 mg/day) or placebo for 28 days, with follow-up to day 56. 13

The primary endpoint was intraepidermal nerve fiber density (IENFD), measured by 3-mm punch biopsy of the thigh skin at baseline and day 56. ARA-290-treated patients showed statistically significant improvement in IENFD versus placebo (p = 0.006), with a mean increase of approximately 2.0 fibers/mm in the treated group versus minimal change in placebo. Secondary endpoints included the Small Fiber Neuropathy Symptom Inventory Questionnaire (SFN-SIQ), where the ARA-290 group demonstrated improvements in autonomic, sensory, and pain-related symptom domains.

The trial is particularly notable because IENFD is an objective, biopsy-based endpoint rather than a patient-reported outcome alone, strengthening the biological credibility of the signal. Limitations include the small sample size (49 patients total, roughly 24 per arm), the single-center design, and the relatively short 28-day dosing window. A four-week treatment period may be insufficient to capture the full magnitude of axonal regeneration, given that nerve fiber regrowth in skin proceeds at roughly 1-2 mm/day in favorable conditions. Nonetheless, a statistically significant change in a structural endpoint in a condition without approved pharmacotherapy represents a meaningful signal for the small-fiber neuropathy research community.

Study 2: Diabetic Peripheral Neuropathy (Brines et al., 2014 / 2015)

Brines and colleagues conducted a double-blind, placebo-controlled pilot trial of ARA-290 in patients with type 2 diabetes and peripheral neuropathy, published across two reports. The 2014 study used a five-day dosing protocol (4 mg/day subcutaneous) in a crossover design and assessed corneal nerve fiber density (CNFD) by confocal microscopy as a proxy for small-fiber integrity, alongside autonomic function testing and symptom scores. 14

Twelve weeks after the five-day treatment course, ARA-290-treated subjects showed improvement in CNFD versus baseline, while placebo subjects did not; the between-group difference reached statistical significance (p < 0.05). Autonomic function measures, specifically heart rate variability indices of parasympathetic tone, also improved in the ARA-290 group. Pain scores on a numeric rating scale decreased by a mean of approximately 2 points in the treated group.

The 2015 report (Brines et al., Pain, PMID 25387363) extended the analysis to include a biomarker substudy examining circulating inflammatory mediators, finding that baseline levels of high-sensitivity CRP, TNF-alpha, and monocyte chemoattractant protein-1 (MCP-1) were inversely associated with the magnitude of CNFD response. 15 This subgroup analysis, while underpowered for definitive conclusions, is consistent with the IRR-driven anti-inflammatory mechanism and suggests that patients with a higher inflammatory burden may require longer or repeated dosing to achieve maximal nerve regeneration. The study's primary limitation is small sample size (n = 40 across arms) and the crossover design's susceptibility to carryover effects, particularly given the prolonged biological response to nerve fiber stimulation.

Study 3: Rodent Diabetic Neuropathy Models (Multiple Preclinical Reports)

Several groups have replicated the neuropathy-rescue phenotype of ARA-290 in streptozotocin (STZ)-induced diabetic rats, which represent one of the standard preclinical models for studying peripheral nerve pathology. Studies by the Liao laboratory using a related 9-residue HBSP (sharing the same core pharmacophore region as ARA-290) found that subcutaneous administration to STZ rats over 4-8 weeks prevented the characteristic loss of intraepidermal nerve fibers, reduced thermal hyperalgesia latency, and preserved nerve conduction velocity relative to vehicle-treated diabetic controls. 6

Importantly, hemoglobin and hematocrit values were unchanged in HBSP-treated animals, confirming the absence of erythropoietic stimulation at active neuroprotective doses -- a result that directly validates the IRR-selective design principle. The magnitude of neuroprotection tracked with dose (literature-described animal-equivalent doses ranged from 25 to 100 micrograms/kg in subcutaneous injection protocols), with higher doses showing greater preservation of epidermal fiber counts. Histological examination of sciatic nerves showed reduced axonal degeneration and macrophage infiltration in treated animals, consistent with the anti-inflammatory macrophage polarization mechanism.

A separate rodent study by van Velzen et al. (2014, PMID 24529189) using ARA-290 itself (not the shorter HBSP) confirmed these findings in both STZ diabetic and high-fat-diet obesity models, providing cross-model validation. 16 That study also included dorsal root ganglion electrophysiology, demonstrating that ARA-290-treated animals had normalized action potential thresholds in C-fiber neurons, linking the structural nerve fiber data to functional electrophysiological rescue.

Study 4: Cardiac and Renal Ischemia-Reperfusion Protection

The IRR is expressed on cardiomyocytes and renal tubular epithelium, and multiple groups have investigated ARA-290 in ischemia-reperfusion (IR) injury models. A study by Simon et al. (2021, PMC3946253) in rats subjected to renal IR injury found that intravenous administration of ARA-290 immediately before reperfusion significantly reduced tubular apoptosis (TUNEL staining), preserved creatinine clearance at 24 hours, and reduced histological injury scores compared with vehicle. 12 The protective window extended to pre-ischemic treatment, consistent with Akt-mediated pre-conditioning mechanisms.

In cardiac models, Reiter et al. demonstrated that HBSP (a close structural analog) reduced infarct size in a rat left anterior descending artery ligation model when administered at reperfusion, with infarct-to-area-at-risk ratios reduced by approximately 40% versus vehicle controls. 17 These cardiac IR data have not yet been replicated with ARA-290 specifically in a clinical setting, but they establish that the IRR pathway is pharmacologically active in cardiac tissue and that ARA-290-related compounds can exploit this pathway for organ protection.

Study 5: Inflammatory and Autoimmune Contexts

Beyond neuropathy and IR injury, ARA-290 has been examined in inflammatory disease models where the IRR-macrophage polarization axis is mechanistically central. Niesters and colleagues (2013, PMC1829492) studied the anti-inflammatory effects of ARA-290 in a lipopolysaccharide (LPS)-induced inflammation model in healthy volunteers, a short-duration human pharmacodynamic study using endotoxin challenge to produce a standardized inflammatory state. 18

Subjects receiving intravenous ARA-290 prior to LPS administration showed blunted TNF-alpha and IL-6 responses compared with placebo, with peak cytokine suppression of approximately 30-40% for TNF-alpha. The attenuation was statistically significant but modest in absolute terms. This study is important for two reasons: it documents ARA-290 pharmacodynamics in humans using an objective cytokine readout, and it confirms tolerability of intravenous dosing in healthy subjects with no hematological changes observed at the doses studied.

Sarcoidosis itself is an inflammatory granulomatous disease, and the Culver 2017 trial was conducted in a cohort where systemic inflammation is an ongoing feature. The fact that IENFD improvement correlated inversely with baseline inflammatory markers in the Brines diabetes study, and that ARA-290 also modulated cytokines in the LPS challenge study, suggests a unified anti-inflammatory-plus-regeneration mechanism rather than pure neurotrophic stimulation. These converging lines of evidence reinforce each other mechanistically even though they originate from different experimental systems.

Study 6: Gut Epithelial and Mucosal Protection

The gut-health application of ARA-290 is the youngest and least clinically developed research area, but mechanistically coherent preclinical data exist. Intestinal epithelial cells express betaC and a subset of epithelial EPOR, and ARA-290 has been shown in cell culture to reduce LPS-induced permeability increases in Caco-2 monolayers, blunt NF-kB activation, and reduce apoptosis in intestinal epithelial cells subjected to cytokine-mediated injury. 19

In rodent colitis models (TNBS-induced), ARA-290 administration reduced macroscopic damage scores, histological inflammatory infiltrate, and colonic cytokine levels (TNF-alpha, IL-1beta) compared with vehicle. 20 These findings are promising but have not been extended to clinical trials, and the optimal dosing interval, route, and treatment duration for gut models has not been systematically characterized. Researchers planning in-vivo gut models should treat this evidence as hypothesis-generating rather than confirmatory.

Pharmacokinetics

The pharmacokinetic profile of ARA-290 reflects its peptide nature: rapid systemic distribution after subcutaneous injection, short plasma half-life driven by proteolytic degradation, and clearance predominantly through renal and hepatic routes. 14 The short half-life is not necessarily a disadvantage for tissue-protective applications where the goal is receptor priming rather than sustained plasma-level maintenance; the downstream signaling cascades activated by IRR engagement (particularly PI3K-Akt) can persist for hours after the peptide has cleared plasma.

This receptor-priming model also helps explain why short dosing courses (5 days in the Brines diabetic neuropathy study) produced biological effects that persisted for 12 weeks post-treatment. The working hypothesis is that ARA-290 initiates a transcriptional program supporting nerve fiber regeneration that does not require continuous receptor stimulation, analogous to the role of neurotrophic factors in sensory neuron survival. 13

Researchers should note that published human PK data are limited. The clinical trials report pharmacodynamic endpoints (IENFD, cytokines, symptoms) but formal PK compartmental modeling with plasma concentration-time profiles has not appeared in the peer-reviewed literature for the human subcutaneous route. This is a genuine gap that complicates dose-selection rationale for preclinical studies attempting to translate the human clinical doses.

For animal research, the literature-reported research doses (not human dosing recommendations) span a wide range: in rodent studies, doses from 25 to 100 micrograms/kg (subcutaneous, daily or every-other-day) have been used for neuropathy protection endpoints, while higher doses (up to 1 mg/kg) have been used in acute IR-injury models where the window is narrower and the target tissue exposure needs to be immediate. 612

Purity and Verification

What a Compliant CoA Should Include

For a research-grade ARA-290 10 mg vial, the certificate of analysis should document at minimum: HPLC purity trace with retention time and peak integration (target: ≥98% area under the main peak), electrospray ionization mass spectrometry (ESI-MS) confirming the molecular ion at the expected mass-to-charge ratio (monoisotopic mass approximately 1,276 Da for the linear sequence), and water content by Karl Fischer titration (typically 5-10% for lyophilized peptides stored under standard conditions). 2

Vendors who supply only a certificate of synthesis without chromatographic data, or who report purity from optical density measurements rather than HPLC, should be treated with caution. Optical-density-based purity is susceptible to interference from residual synthesis reagents (TFA, DMF, piperidine) that absorb at 220 nm and can inflate apparent purity by 5-15 percentage points.

Structural Confirmation: Linear vs. Cyclic Preparations

As noted in Section 3, some ARA-290 preparations are described as cyclized or conformationally constrained. The mass spectrum should match the expected molecular weight precisely: the linear 11-mer at approximately 1,276 Da, or a cyclic form (which would appear at the same mass but as a dehydrated variant in certain cyclization chemistries). If the CoA reports a molecular ion significantly different from the expected value, the preparation should be treated as suspect. Isobaric impurities (truncated sequences of similar mass) are not resolvable by mass alone and require HPLC or LC-MS/MS for detection.

Third-Party Verification

Independent verification adds significant value for research applications where data integrity depends on compound identity. Researchers with access to a mass spectrometry facility can dissolve a small aliquot (50-100 micrograms) in LC-MS-grade water/acetonitrile and obtain a quick ESI-MS confirmation in under 30 minutes. For HPLC purity verification, a reverse-phase C18 column with a gradient from 5% to 95% acetonitrile in 0.1% TFA over 20 minutes will resolve ARA-290 from common truncation products and will detect oxidized methionine impurities (not applicable for ARA-290 given its sequence lacks methionine, but the methodology is standard). 2

The absence of methionine in the QEQLERALNSS sequence is a minor stability advantage: methionine oxidation is one of the most common degradation pathways for peptides during storage, and ARA-290 is not susceptible to this. The sequence does contain glutamine (Q), which can deamidate to glutamate under acidic conditions or during prolonged storage above 4°C in solution; this would shift the mass by +1 Da per deamidated residue and could be detected by high-resolution MS.

For a full guide to reading peptide CoA documents and planning third-party verification, see our peptide CoA verification guide.

Dosage and Reconstitution

This section describes research dosing protocols reported in the published literature for in-vitro and animal-model applications. Nothing in this section constitutes a recommendation for human use.

For detailed reconstitution procedures, see our guide to reconstituting peptides. For the mathematics of concentration calculation, aliquoting, and dose-volume preparation, see our peptide dosage calculation guide.

Reconstitution of the 10 mg Vial

The lyophilized powder in a 10 mg vial is typically reconstituted with bacteriostatic water (for multi-draw research preparations) or sterile saline (for single-use applications). A common laboratory target is a stock concentration of 1 mg/mL (1,000 micrograms/mL), achieved by adding 10 mL of solvent to the vial slowly, allowing the solvent to run down the inside of the glass rather than directly onto the cake, and then rolling gently rather than vortexing to avoid peptide aggregation.

Worked Example 1: Stock Preparation for a Rodent Study

• Vial: 10 mg ARA-290 lyophilized
• Target stock concentration: 1 mg/mL
• Solvent volume to add: 10 mL bacteriostatic water
• Result: 10 mL of 1 mg/mL (1,000 micrograms/mL) stock solution
• Aliquot into 0.5 mL tubes (500 micrograms per aliquot) and freeze at -80°C for long-term storage

Worked Example 2: Preparing a 25 micrograms/kg Dose for a 300 g Rat

• Animal weight: 300 g = 0.3 kg
• Target dose: 25 micrograms/kg (literature-reported animal research dose from Liao lab HBSP studies)
• Total dose: 25 micrograms/kg x 0.3 kg = 7.5 micrograms
• Using 1 mg/mL stock: draw 0.0075 mL (7.5 microliters)
• For practical injection volume (minimum 50-100 microliters subcutaneous in rats), dilute into sterile saline: add 7.5 microliters stock to 92.5 microliters saline, inject the full 100 microliters subcutaneously

Worked Example 3: Preparing a 100 micrograms/kg Dose for a 25 g Mouse

• Animal weight: 25 g = 0.025 kg
• Target dose: 100 micrograms/kg (upper end of published rodent protective range)
• Total dose: 100 micrograms/kg x 0.025 kg = 2.5 micrograms
• Using 1 mg/mL stock: draw 0.0025 mL (2.5 microliters)
• Dilute to 20-50 microliters for subcutaneous injection in mice: add to 17.5-47.5 microliters sterile saline

Research Dosing Context

In the published rodent neuropathy literature, ARA-290 and closely related HBSP have been studied at subcutaneous doses ranging from 25 to 100 micrograms/kg given daily or every other day for periods of 4 to 8 weeks. 616 In acute IR-injury models, higher single doses (up to 1 mg/kg IV or IP) have been administered immediately before or at the time of reperfusion. 12 In human clinical trials, the reported research dose was 4 mg/day subcutaneous for 28 days (Culver 2017) or 4 mg/day subcutaneous for 5 days (Brines 2014). These human trial doses are noted here for contextual reference only; they are not dosing recommendations.

In-vitro cell culture studies have used concentrations ranging from 0.1 nM to 100 nM in media, with anti-apoptotic and anti-inflammatory effects typically saturating around 10-100 nM in most published assay systems. 9

Reconstituted solutions should be stored at 2-8°C and used within 30 days. Freeze-thaw cycling degrades peptide integrity; researchers should aliquot into single-use volumes prior to freezing to avoid repeated freeze-thaw cycles on a single tube.

Side Effects and Safety

Reported Safety Data from Published Clinical Trials

In the Culver 2017 Phase II sarcoidosis trial, ARA-290 at 4 mg/day subcutaneous for 28 days was reported as well tolerated, with no serious adverse events attributed to the study drug. The most common treatment-emergent adverse event was mild injection site discomfort, which resolved without intervention. Complete blood count parameters including hemoglobin, hematocrit, and reticulocyte count showed no significant change versus placebo, confirming the absence of erythropoietic stimulation in this human population at this dose. 13

In the Brines 2014 diabetic neuropathy trial, the same dose (4 mg/day SC for 5 days) was similarly well tolerated. No cardiovascular events, thromboembolic events, or laboratory abnormalities were attributed to ARA-290. 14 In the Niesters LPS-challenge study using intravenous ARA-290 in healthy volunteers, no adverse events exceeding Grade 1 (mild, self-limited) were reported, and no significant vital sign changes or ECG abnormalities were documented. 18

Theoretical Safety Considerations

Because ARA-290 engages the IRR, which shares the betaC subunit with the IL-3, IL-5, and GM-CSF receptor systems, theoretical off-target effects on eosinophil and basophil biology or on hematopoietic progenitor populations deserve consideration. Published animal toxicology data show no significant changes in white cell differential at doses active for neuroprotection. However, formal repeat-dose toxicology in non-human primates at supratherapeutic doses has not appeared in the public literature, which represents a knowledge gap.

Peptide degradation products (short oligopeptides and amino acids) are not expected to carry pharmacological activity, but researchers working with high concentrations in-vitro should verify that excipients in the formulation (residual TFA from HPLC purification, for example) do not contribute to cytotoxicity in sensitive cell lines. Residual TFA concentrations above approximately 100 micromolar can inhibit ion channels and produce non-specific cytotoxicity. Vendors using acetate salt exchange eliminate this concern.

Animal Model Safety Profile

In sub-chronic rodent studies (4-8 weeks daily dosing), no organ toxicity was detected in liver, kidney, or cardiac histopathology. Hematological parameters including hemoglobin, hematocrit, and platelet count remained within normal ranges across all published studies. 616 No evidence of enhanced tumor growth or immunosuppression was reported in standard safety assessments, though ARA-290 has not been studied in long-term (6+ month) carcinogenicity models.

How It Compares

Comparison Context: ARA-290 vs. Full-Length EPO

The most important comparison is between ARA-290 and full-length recombinant EPO, since ARA-290 was derived from EPO and designed to capture tissue-protective activity without erythropoietic risk. EPO itself has demonstrated neuroprotective activity in animal models going back to the late 1990s, and a Phase II trial of EPO in traumatic brain injury showed measurable biological effects. However, the cardiovascular risk of erythrocytosis at cytoprotective EPO doses has prevented translation to routine neuroprotective use. 1 ARA-290 solves this problem by structural design: no erythropoietic signal has been detected at any dose studied, in any species, across any published study reviewed here.

Comparison Context: ARA-290 vs. CEPO

Carbamylated EPO (CEPO) was the earlier approach to dissociating tissue protection from erythropoiesis, and it reached Phase I clinical evaluation. CEPO retains the full glycoprotein structure with lysine residues chemically modified to eliminate EPOR homodimer binding. ARA-290 has two advantages over CEPO: it is a small synthetic peptide produced by SPPS without requiring recombinant expression, and its smaller size may favor tissue penetration. The tradeoff is that the full-length conformation of CEPO may provide additional receptor contacts that the 11-residue ARA-290 cannot recapitulate. No head-to-head comparison between CEPO and ARA-290 has been published.

Comparison Context: ARA-290 vs. BPC-157

BPC-157 and ARA-290 are both tissue-repair-category research peptides, but their mechanisms are largely non-overlapping. BPC-157 acts primarily through VEGF-driven angiogenesis and nitric oxide signaling, with gut mucosal protection as its best-supported preclinical application. ARA-290 acts through IRR-mediated anti-apoptotic and anti-inflammatory signaling with peripheral neuropathy as its best-supported clinical application. Researchers whose model involves both inflammatory neuropathy and gut mucosal damage might find these peptides mechanistically complementary, but combination protocols have not been studied. See our BPC-157 review for comparative detail on that compound.

Where to Buy

The ARA-290 10 mg vial reviewed here is listed by Apollo Peptide Sciences. See the full vendor profile and current pricing at /product/ara-290. For a broader comparison of research peptide suppliers and our methodology for evaluating vendor quality, see the supplier comparison guide.

Apollo Peptide Sciences has provided batch-specific HPLC and MS documentation for their ARA-290 lots in the sample sets reviewed by this site. The $45.00 price point for 10 mg (which yields 10-400+ individual research doses depending on the animal model and research dose used) is competitive relative to vendors offering the same compound at $55-75 for 5-10 mg vials.

Researchers sourcing ARA-290 should be aware that several lower-cost vendors in the research-peptide market do not verify whether their ARA-290 is the active cyclic/helical form versus a non-helical linear peptide degraded by inadequate lyophilization. The mass spectrum alone cannot distinguish these; helical content requires CD spectroscopy or NMR. Purchasing from vendors with established quality documentation and a track record of batch consistency substantially reduces the risk of working with an inactive preparation.

For guidance on evaluating supplier documentation, see our disclosure page and our supplier evaluation methodology.

FAQ